viernes, 14 de septiembre de 2012

Safety Information > August 2012

Safety Information > August 2012




The MedWatch August 2012 Safety Labeling Changes posting includes 53 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.

The "Summary Page" provides a listing of drug names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm315860.htm
The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and/or WARNINGS sections: 


Aplenzin (Bupropion Hydrobromide)
Atrovent HFA (Ipratropium Bromide HFA)
Avelox (Moxifloxacin Hydrochloride)
Bactrim (Sulfamethoxazole and Trimethoprim)
Capoten (Captopril)
Coartem (Artemether/Lumefantrine)
Complera (Emtricitabine, Rilpivirine, Tenofovir
Diovan (Valsartan)Bactrim DS (Sulfamethoxazole and Trimethoprim)
Diovan HCT (Valsartan/Hydrochlorothiazide)
Disoproxil Fumarate)
Edurant (Rilpivirine)
Fuzeon (Enfuvirtide)
Intelence (Etravirine)
Invega Sustenna (Paliperidone Palmitrate)
Isentress (Raltegravir)
Lamictal (Lamotrigine) and Lamictal XR (Lamotrigine)
Leustatin (Cladribine)
Lovaza (Omega-3-Acid Ethyl Esters)
Lucentis (Ranibizumab)
Mirapex (Pramipexole Dihydrochloride) and Mirapex ER (Pramipexole Dihydrochloride)
Moviprep (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid)
Neoral Soft Gelatin (Cyclosporine)
Neoral oral Solution (Cyclosporine)
Nexavar (Sorafenib)
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
Ortho Evra (Norelgestromin/Ethinyl Estradiol)
Oxaliplatin (Oxaliplatin)
Revatio (Sildenafil)
Sanctura XR (Trospium Chloride)
Sandimmune (Cyclosporine, USP)
Selzentry (Maraviroc)
Strattera (Atomoxetine Hydrochloride)
Sustiva (Efavirenz)
Toviaz (Fesoterodine Fumarate)
Tradjenta (Linagliptin)
Trobicin (Spectinomycin)
Ultane and Ultane NovaPlus (Sevoflurane)
Vectibix (Panitumumab)
Viread (Tenofovir Disoproxil Fumarate


The summary view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. The “quick view” table below provides the drug name and sections modified. Click on the drug name to go to the detailed view. The detailed view includes sections and subsections modified, a description of new or modified safety information in the BOXED WARNING, CONTRAINDICATIONS, or WARNINGS sections, and a link to the revised prescribing information.
Key to Label Section Acronyms:
BW=BOXED WARNING, C=CONTRAINDICATIONS, W=WARNINGS, P=PRECAUTIONS
AR=ADVERSE REACTIONS, PPI/MG=PATIENT PACKAGE INSERT/MEDICATION GUIDE
DRUG NAME
SECTIONS MODIFIED
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
XXX X
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
XX
XXX
XXXXPCI
XX X
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
XX
XX
X
XX
Diovan HCT (Valsartan/Hydrochlorothiazide)11XX X PCI
XX
XXPCI/PI
XX
XX X
XX
XX
XXX
XX
XX
XX
XX
XX X
XX XPI
XX
XX PL
XX
XX X
XXX
XXPCI/MG
Strattera (Atomoxetine Hydrochloride) Capsules32XX
Sustiva (Efavirenz) Capsules and Tablets33XX
XXX
XX X
X
X
XX X
XX
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
X
XPPI
X
XPI
X
X
X
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
X
X
PCI
X
X
Gralise (Gabapentin) Tablets51
X
X
X
(Click on drug name to go to detailed view)
BW
C
W
P
AR
PPI/MG
MG
Zyprexa Relprevv (Olanzapine) for Extended-release Injectable Suspension55MG

No hay comentarios:

Publicar un comentario